Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Withdrawn before enrolling · Phase 2

Conditions studied: Thrombocytopenia

In brief

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

Key facts

Study ID

NCT01194167

Run by

University of Cincinnati

People needed

0

Starts

2010-08-01

Expected to finish

2012-01-01

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Laboratory diagnosis of platelet refractoriness
• Diagnosis of platelet dependence
• Adequate liver and renal laboratory screening tests

You may not qualify if…

• Patients with thrombocytopenia that are responsive to platelet therapy
• Patients actively receiving intravenous immunoglobulin, plasmapheresis or cytotoxic medications for thrombocytopenia

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.